**Background**
Viral infections caused by RNA viruses, such as the Hepatitis C virus (HCV) and the Dengue virus, pose significant global health threats. A critical step in the replication cycle of these viruses is the synthesis of viral RNA, which is catalyzed by the RNA-dependent RNA polymerase (RdRp). Because RdRp is essential for viral genome replication and is not present in human cells, it serves as a high-priority therapeutic target for the development of potent antiviral agents. Inhibiting this enzyme can effectively block viral proliferation and reduce the viral load in infected patients. In this context, we will introduce a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase – Balapiravir.
**Definition**
Balapiravir (also known as Ro 4588161 or R1626) is an orally active proagent of a nucleoside analogue inhibitor that targets the RNA polymerase. According to the Balapiravir description, it serves as a precursor to the active metabolite R1479 (4′-Azidocytidine).
**In Vitro and In Vivo Studies**
From a chemical perspective, the Balapiravir Formula is C21H30N6O8 with a molecular weight of 494.50. Beyond its antiviral properties, it is a versatile click chemistry reagent containing an azide group. This allows it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups. Regarding Balapiravir biological activity, the compound has demonstrated significant anti-HCV activity.
In terms of Balapiravir in vivo efficacy, studies using CD-1 mice showed that after oral dosing of 28.1 mg/kg, the active metabolite R1479 reached a maximum plasma concentration (Cmax) of 24.38 μM at 2 hours post-dosing and a minimum concentration (Cmin) of 6.34 μM at 24 hours post-dosing. These pharmacokinetic properties highlight its potential as an orally bioavailable antiviral candidate. In conclusion, Balapiravir is a potent RNA polymerase inhibitor and a useful click chemistry tool for antiviral research.
Keywords
Balapiravir, 690270-29-2, Ro 4588161, R1626, Ro4588161, Ro-4588161, R 1626, R-1626, HCV, DNA/RNA Synthesis, Hepatitis C virus, orally, nucleoside, RdRp
References
[1] Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450.
[2] Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31.
[3] Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88(3):1740-7.